[Thrombotic microangiopathy and cancer]

Area of Science:

• Nephrology
• Oncology
• Hematology

Background:

• Thrombotic microangiopathy (TMA) is a critical condition causing hemolytic anemia, thrombocytopenia, and organ damage, particularly in the kidneys and brain.
• TMA accounts for 15% of acute kidney injury in cancer patients, often triggered by anti-angiogenic agents or chemotherapy.
• Iatrogenic TMA presents in two types: Type I (chemotherapy-induced) causes chronic, dose-dependent renal injury, while Type II (anti-angiogenic agent-induced) has dose-independent renal effects with potential for recovery upon drug cessation.

Purpose of the Study:

• To elucidate the mechanisms of endothelial lesions in thrombotic microangiopathy (TMA).
• To inform current management strategies for TMA, especially in oncological settings.
• To highlight the evolving treatment landscape for TMA, including the role of immunosuppressive therapy.

Main Methods:

• Analysis of complement activation pathways.
• Investigation of regulatory factors involved in endothelial damage.
• Review of clinical outcomes and treatment responses in TMA patients.

Main Results:

• Understanding complement activation and regulatory factors has improved insight into TMA's endothelial lesions.
• Differentiated mechanisms and outcomes between chemotherapy-induced (Type I) and anti-angiogenic agent-induced (Type II) iatrogenic TMA.
• Identified a trend towards using immunosuppressive agents for recurrent or plasmapheresis-refractory TMA.

Conclusions:

• Current research focuses on understanding TMA pathogenesis to guide effective treatment.
• While evidence-based guidelines are lacking, insights into endothelial damage mechanisms are shaping therapeutic approaches.
• Immunosuppressive agents are increasingly considered for managing challenging cases of TMA, particularly those resistant to plasmapheresis.